ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX

Wed Feb 20, 2013 12:01pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130220:nHUGcX9z


GHENT, Belgium, 20 February 2013 - Ablynx [Euronext Brussels: ABLX], a biopharmaceutical company
engaged in the discovery and development of Nanobodies(R), a novel class of therapeutic proteins
based on single-domain antibody fragments for a range of serious human diseases, today announced
its promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID). Ablynx will be included in
the BELMID Index as of the 18th of March 2013.

The entry of Ablynx to the BELMID Index is a result of performance of the Ablynx shares and is
based on Ablynx's market capitalisation, free float and liquidity in the period up to end of
January 2013. 

About Ablynx

Ablynx http://www.ablynx.com/  is a biopharmaceutical company engaged in the discovery and
development of Nanobodies®
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/ , a
novel class of therapeutic proteins based on single-domain antibody fragments, for a range of
serious human diseases, including inflammation, haematology, oncology and pulmonary disease.
Today, the Company has approximately 25 programmes in the pipeline
http://www.ablynx.com/en/research-development/pipeline/  and five Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant partnerships with
major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck &
Co. The Company is headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com http://www.ablynx.com/ .

For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / 
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com mailto:edwin.moses@ablynx.com 

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03 
e:  marieke.vermeersch@ablynx.com  mailto:marieke.vermeersch@ablynx.com%20 
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com mailto:ablynx@mcomgroup.com

press release in pdf format http://hugin.info/137912/R/1679682/548575.pdf 


----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1679682